Sugi Predict

Sugi Predict / Targets / PDE2A

PDE2A

cGMP-dependent 3',5'-cyclic phosphodiesterase · O00408 · PDE2A on Sugi Atlas →

112,788 patent compounds predicted against PDE2A, 46,488 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL84521 SCHEMBL84521 0.70 15/20
SCHEMBL55774 SCHEMBL55774 0.64 14/20
SCHEMBL310126 SCHEMBL310126 0.59 14/20
SCHEMBL130521 SCHEMBL130521 0.60 13/20
SCHEMBL359546 SCHEMBL359546 0.51 11/20
SCHEMBL171619 SCHEMBL171619 0.55 9/20
Clofarabine Clofarabine (SCHEMBL9040) 1.00 8/20
Cilostamide Cilostamide (SCHEMBL49742) 0.66 8/20
SCHEMBL380188 SCHEMBL380188 0.48 8/20
SCHEMBL354647 SCHEMBL354647 0.44 8/20
SCHEMBL356013 SCHEMBL356013 0.58 7/20
SCHEMBL309075 SCHEMBL309075 0.49 7/20
SCHEMBL359148 SCHEMBL359148 0.49 7/20
SCHEMBL403861 SCHEMBL403861 0.45 7/20
SCHEMBL150245 SCHEMBL150245 0.59 6/20
SCHEMBL169419 SCHEMBL169419 0.45 6/20
SCHEMBL355769 SCHEMBL355769 0.44 6/20
SCHEMBL266467 SCHEMBL266467 0.40 6/20
SCHEMBL172558 SCHEMBL172558 0.38 6/20
SCHEMBL359027 SCHEMBL359027 0.38 6/20

Clinical trials — most relevant to PDE2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension PHASE4COMPLETED
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer PHASE3RECRUITING
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate PHASE2/PHASE3RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Effect of Tadalafil on Cerebral Large Arteries in Stroke PHASE2COMPLETED
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study PHASE2UNKNOWN
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH) PHASE2RECRUITING
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response EARLY_PHASE1UNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
Endurance Performance at Altitude nanCOMPLETED
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia nanUNKNOWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE2A binder may also engage these)

ProteinNameSimilarity
Q922S4 — 1.000 Q922S4 →
P14099 — 1.000 P14099 →
Q01062 — 0.999 Q01062 →
E9Q4S1 — 0.989 E9Q4S1 →
P34094 — 0.989 P34094 →
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.988 landscape →
B0R0W9 — 0.988 B0R0W9 →
O70628 — 0.988 O70628 →
PDE8A High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A 0.987 landscape →
I1MGE5 — 0.987 I1MGE5 →
P14714 — 0.987 P14714 →
P15001 — 0.987 P15001 →
P14712 — 0.987 P14712 →
DAPK1 Death-associated protein kinase 1 0.987 landscape →
P70600 — 0.987 P70600 →
A2XLG5 — 0.987 A2XLG5 →
INPP5B Type II inositol 1,4,5-trisphosphate 5-phosphatase 0.986 landscape →
Q8K337 — 0.986 Q8K337 →
Q80YE7 — 0.986 Q80YE7 →
JAK3 Tyrosine-protein kinase JAK3 0.986 landscape →
O95759 — 0.986 O95759 →
D3ZEY4 — 0.986 D3ZEY4 →
P30733 — 0.986 P30733 →
Q61586 — 0.986 Q61586 →
B7ZC32 — 0.986 B7ZC32 →
Q38998 — 0.986 Q38998 →
O88502 — 0.986 O88502 →
Q6DNF7 — 0.985 Q6DNF7 →
Q10CQ8 — 0.985 Q10CQ8 →
P06593 — 0.985 P06593 →